David Graham’s Personal Experience with Nutrigenetic Testing, Part 1
Toronto Star Life writer David Graham recently had one of the most thorough medical check-ups a person can undergo at Scienta Health. And, of course, it included genetic analysis performed by Genosense Diagnostics.
Genosense, says [Dr. Elaine] Chin, is one of the most comprehensive providers of preventive genetic analysis in the world. I will learn what bad genes I have and, perhaps more importantly, I will learn how my genes metabolize food and medications.
She says the results will also reveal “nutrigenomics — the interaction of nutrition and one’s genes, and pharmocogenitics, the interaction of drugs, its effectiveness and toxicity risks with medications and hormones.”
…
The science offers pure data that can be a motivator for change. It’s the precision of this information that allows doctors to tell patients why one person can’t drink coffee while another can or one person needs more exercise than another.
David Graham shares the results of his tests next week. I’m very curious to see how he reacts. So far, I picture him as a wide-eyed lamb.
Toronto Star, September 29, 2006
Technorati Tags: genetics, genes, dna, genetic testing, health, scienta health, scienta, genosense
Comments
2 Responses to “David Graham’s Personal Experience with Nutrigenetic Testing, Part 1”Trackbacks
Check out what others are saying about this post...[...] Last week, Toronto Star Life writer wrote about his check-up at Scienta Health. The results from his tests are back. First and foremost, I apparently have two genes that promote longevity, interleukin 6 and 10. These genes are “over represented in males centurians,” according to Chin. [...]
[...] And if Maggie Bullock had asked me what I think of all this? I would have said that people have the freedom to throw away use their money as they wish and in some cases, people really do find the nutrigenetic tests to be a great source of motivation. But it’s not a sure-death situation for those of us who don’t avail ourselves of these services, choosing instead to live moderately. In the end, it all comes to commercial value and right now, DNA-selected products are hot and getting hotter as genomic technology improves and becomes cheaper. [...]